Eisai Co Ltd - Company Profile
Powered by 
All the sales intelligence you need on Eisai Co Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Eisai Co Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Eisai Co Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Eisai Co Ltd (Eisai) is a pharmaceutical company that discovers, develops, manufactures and markets pharmaceuticals, including prescription medicines, OTC drugs and generics. The company’s franchise areas in research include neurology and oncology. Eisai’s major products include LEQEMBI for the treatment of early-stage Alzheimer's disease; Lenvima for treatment of endometrial carcinoma; Dayvigo which is being developed for the treatment of insomnia; Halaven, an anti-cancer agent; and Fycompa tablets for the treatment of epilepsy and peripheral neuropathy. Eisai has production plants in Japan, the UK, China, and India and laboratories in Japan, the US, and the UK; operations in the Americas, Asia and Latin America, EMEA and Oceania with overseas sales offices in the US, Germany, France, China, and South Korea. Eisai is headquartered in Tokyo, Japan.
Headquarters
Japan
Address
Eisai Main Bldg., 4-6-10, Koishikawa, Bunkyo-Ku, Tokyo, 112-8088
Website
www.eisai.co.jp
Telephone
81 3 38173700
No of Employees
13,506
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4523 (TYO)
Revenue (2024)
$5.2B
6.4%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
9.5%
(2024 vs 2023)
Market Cap*
$8.4B
Net Profit Margin (2024)
XYZ
2.8%
(2024 vs 2023)
* As of and is in US$
Eisai Co Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Lenvima |
| Dayvigo |
| Fycompa |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Corporate Changes/Expansions | In March, the company launched the Eisai Global Capability Center within the Eisai Knowledge Center in Visakhapatnam, Andhra Pradesh, India. |
| 2026 | Contracts/Agreements | In February, the company entered into a manufacturing license agreement with Shanghai Henlius Biotech, Inc. for the anti-PD-1 antibody serplulimab in Japan. |
| 2025 | Regulatory Approval | In September, the company received fast-track designation from the U.S. Food and Drug Administration for etalanetug, an investigational anti-MTBR (microtubule binding region) tau antibody. |
Competitor Comparison
| Key Parameters | Eisai Co Ltd | Takeda Pharmaceutical Co Ltd | Astellas Pharma Inc | Chugai Pharmaceutical Co Ltd | Ono Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Bunkyo-Ku | Chuo-Ku | Chuo-Ku | Chuo-Ku | Osaka |
| State/Province | Tokyo | Tokyo | Tokyo | Tokyo | Osaka |
| No. of Employees | 13,506 | 47,455 | 13,643 | 7,872 | 4,287 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Fumihiko Ike | Chairman | Executive Board | 2023 | - |
| Haruo Naito | Chief Executive Officer; Director; Representative Corporate Officer | Executive Board | 2014 | - |
| Keisuke Naito | Representative Corporate Officer; Executive Vice President; Chief Operating Officer | Senior Management | - | - |
| Tatsuyuki Yasuno | Chairman - Eisai Inc; Chief Executive Officer - Eisai Inc; President - Americas Region; Senior Vice President | Executive Board | 2023 | - |
| Gary Hendler | Chairman - Eisai Europe Ltd; Chief Executive Officer - Eisai Europe Ltd; President - EMEA Region; Senior Vice President | Executive Board | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer